SCYNEXIS INC
SCYNEXIS INC (SCYX): 5 pipeline candidates · 1 upcoming catalyst · ~22 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.0 months
D/E 0.88 · 0% dilution
Lead: Approved
5 candidates
1 upcoming, next in ~4740d
1 buy · 0 sells (180d)
A transparent, data-derived signal for SCYNEXIS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$324.9M
Cash
$36.9M
Quarterly Burn
$8.1M
Runway
22.0 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| brexafemme | Approved |
| echinocandin | Phase 3 |
| ibrexafungerp | Phase 3 |
| scy-078 | Phase 3 |
| scy-247 | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
42
Total value held
$21.3M
| Holder | Shares | Value |
|---|---|---|
| great point partners llc | 7,554,347 | $6.9M |
| avidity partners management lp | 4,163,320 | $3.8M |
| vanguard capital management llc | 3,128,796 | $2.9M |
| heights capital management, inc | 2,086,960 | $1.9M |
| kingdon capital management, l.l.c. | 1,982,491 | $1.8M |
| dafna capital management llc | 1,086,956 | $997K |
| millennium management llc | 622,161 | $570K |
| geode capital management, llc | 486,368 | $446K |
| blackrock, inc. | 332,194 | $305K |
| vanguard fiduciary trust co | 225,736 | $207K |
Showing top 10 of 42 institutional holders of SCYNEXIS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SCYNEXIS INC's pipeline?
SCYNEXIS INC (SCYX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SCYNEXIS INC's lead drug candidate?
SCYNEXIS INC's most advanced tracked candidate is brexafemme (Approved) for vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).
What is SCYNEXIS INC's next catalyst?
SCYNEXIS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: BREXAFEMME" — expected June 10, 2039.
What is SCYNEXIS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SCYNEXIS INC has approximately 22.0 months of cash runway.
What is SCYNEXIS INC's market capitalization?
SCYNEXIS INC's market capitalization is approximately $324.9M.
Get the full picture on SCYNEXIS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.